Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 992561114 | 9925611 | 14 | F | 20131213 | 20160810 | 20140226 | 20160815 | EXP | US-GLAXOSMITHKLINE-A1044644A | GLAXOSMITHKLINE | 45.89 | YR | F | Y | 0.00000 | 20160815 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 992561114 | 9925611 | 1 | PS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | DOSE: 32 NG/KG/MINCONCENTRATION: 45,000 NG/MLPUMP RATE: 80 ML/DAYVIAL STRENGTH: 1.5 MG | U | P508 | 20444 | 32 | DF | POWDER FOR INFUSION | |||||
| 992561114 | 9925611 | 2 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | UNK | U | R271A | 20444 | POWDER FOR INFUSION | ||||||||
| 992561114 | 9925611 | 3 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | UNK | U | R614 | 20444 | POWDER FOR INFUSION | ||||||||
| 992561114 | 9925611 | 4 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | UNK | U | S276 | 20444 | POWDER FOR INFUSION | ||||||||
| 992561114 | 9925611 | 5 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | UNK | U | S506 | 20444 | POWDER FOR INFUSION | ||||||||
| 992561114 | 9925611 | 6 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | UNK, Z | U | S925 | 20444 | POWDER FOR INFUSION | ||||||||
| 992561114 | 9925611 | 7 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | 32 NG/KG/MIN | U | T794 | 20444 | POWDER FOR INFUSION | ||||||||
| 992561114 | 9925611 | 8 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | 32 NG/KG/MIN, CO | U | U052 | 20444 | 32 | DF | POWDER FOR INFUSION | ||||||
| 992561114 | 9925611 | 9 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 32 NG/KG/MIN CONTINUOUSLY | U | U631 | 20444 | 32 | DF | POWDER FOR INFUSION | |||||
| 992561114 | 9925611 | 10 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 32 NG/KG/MIN (CONCENTRATION 45,000, PUMP RATE 80 ML/DAY, VIAL STRENGTH 1.5 MG), CO | U | Z606 | 20444 | POWDER FOR INFUSION | |||||||
| 992561114 | 9925611 | 11 | C | COUMADIN | WARFARIN SODIUM | 1 | U | 0 | |||||||||||
| 992561114 | 9925611 | 12 | C | TRACLEER | BOSENTAN | 1 | U | 0 | |||||||||||
| 992561114 | 9925611 | 13 | C | ADCIRCA | TADALAFIL | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 992561114 | 9925611 | 1 | Pulmonary arterial hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 992561114 | 9925611 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 992561114 | 9925611 | Catheter removal | |
| 992561114 | 9925611 | Catheter site infection | |
| 992561114 | 9925611 | Central venous catheterisation | |
| 992561114 | 9925611 | Device breakage | |
| 992561114 | 9925611 | Device related infection | |
| 992561114 | 9925611 | Infection | |
| 992561114 | 9925611 | Skin infection | |
| 992561114 | 9925611 | Soft tissue infection | |
| 992561114 | 9925611 | Staphylococcal infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 992561114 | 9925611 | 1 | 19991027 | 0 | ||
| 992561114 | 9925611 | 2 | 19991027 | 0 | ||
| 992561114 | 9925611 | 3 | 19991027 | 0 | ||
| 992561114 | 9925611 | 4 | 19991027 | 0 | ||
| 992561114 | 9925611 | 5 | 19991027 | 0 |